Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MBRX | US
-0.18
-6.82%
Healthcare
Biotechnology
30/06/2024
02/06/2026
2.46
2.65
2.69
2.40
Moleculin Biotech Inc. a clinical stage pharmaceutical company focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors as well as pancreatic cancer and other malignancies. It is also developing WP1220 an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston Texas.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
97.9%1 month
78.9%3 months
67.6%6 months
106.0%-
-
0.42
0.03
0.02
0.52
-
-
-27.60M
7.00M
7.00M
-
-
-
-
-86.82
4.17
6.23
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.88
Range1M
0.95
Range3M
1.16
Rel. volume
1.32
Price X volume
938.15K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cyclerion Therapeutics Inc | CYCN | Biotechnology | 3.02 | 7.60M | -1.95% | n/a | 0.00% |
| Common Stock | ADXN | Biotechnology | 6.4 | 6.84M | -3.76% | n/a | 0.25% |
| XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 2.2 | 6.62M | -0.90% | n/a | 3.09% |
| Oragenics Inc | OGEN | Biotechnology | 0.61 | 6.43M | 0.83% | n/a | 0.00% |
| China SXT Pharmaceuticals Inc | SXTC | Drug Manufacturers-Specialty & Generic | 1.78 | 6.19M | 5.95% | n/a | 19.00% |
| Biofrontera Inc. Common Stock | BFRI | Drug Manufacturers-Specialty & Generic | 1.03 | 5.71M | 7.94% | n/a | 13.20% |
| Galera Therapeutics Inc | GRTX | Biotechnology | 0.101 | 5.60M | 1.00% | n/a | -0.87% |
| Aptorum Group Limited | APM | Biotechnology | 0.976 | 5.34M | -8.79% | n/a | 13.53% |
| Xenetic Biosciences Inc | XBIO | Biotechnology | 3.38 | 5.21M | 2.11% | n/a | 0.00% |
| Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 4.35 | 5.14M | -7.45% | n/a | 0.22% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.71 | 4.37M | 1.18% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0063 | 580.95K | 12.50% | n/a | -37.05% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4821 | 265.64K | -11.54% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.52 | - | Par |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.42 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 67.63 | - | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 7.00M | - | Emerging |